Zurcher Kantonalbank Zurich Cantonalbank Grows Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 5.3% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 52,530 shares of the company’s stock after buying an additional 2,667 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Recursion Pharmaceuticals were worth $346,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Allspring Global Investments Holdings LLC purchased a new stake in shares of Recursion Pharmaceuticals in the third quarter valued at approximately $25,000. Farther Finance Advisors LLC raised its position in Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after acquiring an additional 4,091 shares during the period. GAMMA Investing LLC lifted its holdings in Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after purchasing an additional 6,036 shares in the last quarter. KBC Group NV grew its position in shares of Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after purchasing an additional 3,377 shares during the period. Finally, Amalgamated Bank increased its stake in shares of Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on RXRX shares. Jefferies Financial Group lowered their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Leerink Partners dropped their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Finally, Needham & Company LLC reissued a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, November 20th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $9.25.

Insider Buying and Selling

In related news, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the transaction, the chief financial officer now owns 1,499,631 shares in the company, valued at $11,487,173.46. The trade was a 0.99 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total value of $87,455.08. Following the sale, the director now directly owns 7,066,113 shares of the company’s stock, valued at $53,985,103.32. The trade was a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 134,235 shares of company stock worth $895,538 in the last quarter. 15.75% of the stock is owned by insiders.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $8.01 on Monday. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -5.24 and a beta of 0.85. The company has a fifty day simple moving average of $6.61 and a two-hundred day simple moving average of $7.32. Recursion Pharmaceuticals, Inc. has a 52 week low of $5.60 and a 52 week high of $15.74. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The business had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company’s revenue was up 147.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.43) earnings per share. As a group, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.